Edward H. Lin, MD
Dr. Edward Lin: Finding balance and an innovation source in the great Northwest
Dr. Lin specializes in the treatment of gastrointestinal malignancies particularly colorectal cancer. He is an associate professor of medicine at the University of Washington, an attending medical oncologist at Seattle Cancer Care Alliance, and an associate member of Fred Hutchinson Cancer Research Center.
“Oncology is a demanding and challenging field,” he says. But he is finding a balance between his passions of providing patient care, conducting leading-edge research, and enjoying the beautiful Pacific Northwest with his family.
Certified in Internal Medicine and Medical Oncology, Dr. Lin came to SCCA from MD Anderson Cancer Center in Houston, Texas, where he served as an assistant professor specializing in colorectal cancer research and treatment for five years prior to moving to Seattle. “I am excited to be here to make things happen at Seattle Cancer Care Alliance. This place is ever so green,” he says. “I am finding it to be my source for innovation.”
Education and training
Dr. Lin earned his degree in medicine from the China Medical University in China. He continued his postgraduate study in experimental hematology from the Institute of Basic Medical Sciences in Beijing and then at the Kenneth Norris Cancer Center at USC School of Medicine in Los Angeles. Prior to his residency in medicine at Brown University School of Medicine in Providence, Rhode Island, Dr. Lin was as a senior research associate at Amgen, Inc., a top US biotechnology company based in Thousand Oaks, CA. He received his medical oncology training from Beth Israel Deaconess Medical Center, Harvard Medical School, in Boston.
“Oncology is a profession that requires special energy and patience. Burnout is often described in oncology, but for me, it’s the opposite,” Dr. Lin says. “My patients charge me up and in turn I charge them up. It’s a chain reaction. I value the eternal relationship and trust that we build between us.”
Dr. Lin is currently leading a National Cancer Institute-sponsored phase-III study that examines whether Celecoxib can mitigate painful swelling in the hands and feet of patients taking Capecitabine.
In his work, Dr. Lin has observed increased complete response when combining chemotherapy and radiation for metastatic colorectal cancer; he is trying to decipher the molecular signatures, which are similar to rectal cancer. For the past four years, Dr. Lin has been the chief architect of a book project called: “Cancer Matrix Manual,” which will appear in three languages: English, Chinese, and Spanish, and will be supported by a functional Web site.
Dr. Lin has led nearly two dozen research protocols, edited and/or written many articles and book chapters. He has two pending patent applications including one on endothelial progenitor cell marker. He is on the editorial boards of journal of cell therapy, and is a member of the American Society of Clinical Oncology and American Association for Cancer Research, among others.
He resides in Bellevue, Washington with his wife Michelle and three wonderful children Katie, Danny, and Sarah.
Edward H. Lin, MDDr. Lin is a medical oncologist who specializes in treating gastrointestinal cancers. Read more about Dr. Lin and his work at SCCA.
Patient Care Philosophy:
When caring for patients, I believe in tender, loving, empowering care, with a strong partnership, for a shared, very personal journey.
- Associate Professor, Oncology Division, University of Washington School of Medicine
- Associate Member, Fred Hutchinson Cancer Research Center
Education And Training
- MD: China Medical University, Shenyang, China
- Internal Medicine Residency: Brown University, Providence, RI
- Post-Doctoral Fellow in Hematology/Oncology: Beth Isreal Deconess Medical Center, Harvard Medical School, Boston, MA
More InformationFor more information about Dr. Edward H. Lin's clinical and research expertise, click here.
- Paclitaxel w/wo Ramucirumab in Metastatic Gastric Cancer (UW10036)
- Dalotuzumab + Irinotecan vs Cetuximab +Irinotecan for Metastatic Rectal Cancers (20111765)
- Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)